GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Cyclically Adjusted FCF per Share

Bio-Techne (FRA:TE1) Cyclically Adjusted FCF per Share : €1.28 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Bio-Techne's adjusted free cash flow per share for the three months ended in Mar. 2024 was €0.370. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.28 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Bio-Techne's average Cyclically Adjusted FCF Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 9.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Bio-Techne was 38.70% per year. The lowest was 3.90% per year. And the median was 14.10% per year.

As of today (2024-05-21), Bio-Techne's current stock price is €76.50. Bio-Techne's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €1.28. Bio-Techne's Cyclically Adjusted Price-to-FCF of today is 59.77.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Techne was 125.91. The lowest was 24.76. And the median was 47.38.


Bio-Techne Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted FCF per Share Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.80 0.88 1.15 1.20

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.20 1.25 1.23 1.28

Competitive Comparison of Bio-Techne's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted Price-to-FCF falls into.



Bio-Techne Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.37/131.7762*131.7762
=0.370

Current CPI (Mar. 2024) = 131.7762.

Bio-Techne Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.178 100.560 0.233
201409 0.161 100.428 0.211
201412 0.178 99.070 0.237
201503 0.160 99.621 0.212
201506 0.180 100.684 0.236
201509 0.153 100.392 0.201
201512 0.207 99.792 0.273
201603 0.206 100.470 0.270
201606 0.200 101.688 0.259
201609 0.141 101.861 0.182
201612 0.245 101.863 0.317
201703 0.131 102.862 0.168
201706 0.267 103.349 0.340
201709 0.219 104.136 0.277
201712 0.183 104.011 0.232
201803 0.096 105.290 0.120
201806 0.329 106.317 0.408
201809 0.195 106.507 0.241
201812 0.238 105.998 0.296
201903 0.198 107.251 0.243
201906 0.250 108.070 0.305
201909 0.174 108.329 0.212
201912 0.318 108.420 0.387
202003 0.231 108.902 0.280
202006 0.154 108.767 0.187
202009 0.292 109.815 0.350
202012 0.397 109.897 0.476
202103 0.332 111.754 0.391
202106 0.560 114.631 0.644
202109 0.219 115.734 0.249
202112 0.488 117.630 0.547
202203 0.322 121.301 0.350
202206 0.516 125.017 0.544
202209 0.290 125.227 0.305
202212 0.340 125.222 0.358
202303 0.224 127.348 0.232
202306 0.413 128.729 0.423
202309 0.265 129.860 0.269
202312 0.391 129.419 0.398
202403 0.370 131.776 0.370

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Bio-Techne  (FRA:TE1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=76.50/1.28
=59.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Techne was 125.91. The lowest was 24.76. And the median was 47.38.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Bio-Techne Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (FRA:TE1) Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (FRA:TE1) Headlines

No Headlines